Literature DB >> 15304426

The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol.

Bonnie Wang1, Rosa I Sanchez, Ronald B Franklin, David C Evans, Su-Er W Huskey.   

Abstract

The role of specific cytochrome P450 (P450) isoforms in the metabolism of ethinylestradiol (EE) was evaluated. The recombinant human P450 isozymes CYP1A1, CYP1A2, CYP2C9, CYP2C19, and CYP3A4 were found to be capable of catalyzing the metabolism of EE (1 microM). Without exception, the major metabolite was 2-hydroxy-EE. The highest catalytic efficiency (Vmax/Km) was observed with rCYP1A1, followed by rCYP3A4, rCYP2C9, and rCYP1A2. The P450 isoforms 3A4 and 2C9 were shown to play a significant role in the formation of 2-hydroxy-EE in a pool of human liver microsomes by using isoform-specific monoclonal antibodies, in which the inhibition of formation was approximately 54 and 24%, respectively. The involvement of CYP3A4 and CYP2C9 was further confirmed by using selective chemical inhibitors (i.e., ketoconazole and sulfaphenazole). The relative contribution of each P450 isoform to the 2-hydroxylation pathway was obtained from the catalytic efficiency of each isoform normalized by its relative abundance in the same pool of human liver microsomes, as determined by quantitative Western blot analysis. Collectively, these results suggested that multiple P450 isoforms were involved in the oxidative metabolism of EE in human liver microsomes, with CYP3A4 and CYP2C9 as the major contributing enzymes. Copyright 2004 The American Society for Pharmacology and Experimental Therapeutics

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15304426     DOI: 10.1124/dmd.104.000182

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  30 in total

1.  Potent inhibition of human sulfotransferase 1A1 by 17α-ethinylestradiol: role of 3'-phosphoadenosine 5'-phosphosulfate binding and structural rearrangements in regulating inhibition and activity.

Authors:  Katie Jo Rohn; Ian T Cook; Thomas S Leyh; Susan A Kadlubar; Charles N Falany
Journal:  Drug Metab Dispos       Date:  2012-05-16       Impact factor: 3.922

Review 2.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Authors:  Hongjian Zhang; Donghui Cui; Bonnie Wang; Yong-Hae Han; Praveen Balimane; Zheng Yang; Michael Sinz; A David Rodrigues
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

3.  Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.

Authors:  Samantha Abel; Deborah Russell; Lyndsey A Whitlock; Caroline E Ridgway; Gary J Muirhead
Journal:  Br J Clin Pharmacol       Date:  2008-04       Impact factor: 4.335

4.  Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive.

Authors:  Maribel Reyes; Patrick Brossard; Didier Chassard; Matthias Hoch; Jasper Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  2013-12-22       Impact factor: 2.953

5.  Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives.

Authors:  Monique Groen-Wijnberg; Jan van Dijk; Walter Krauwinkel; Virginie Kerbusch; John Meijer; Reiner Tretter; Wenhui Zhang; Marcel van Gelderen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

Review 6.  Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives.

Authors:  Victoria Tittle; Lauren Bull; Marta Boffito; Nneka Nwokolo
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

Review 7.  A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products.

Authors:  Andrew Stolbach; Karolina Paziana; Harry Heverling; Paul Pham
Journal:  J Med Toxicol       Date:  2015-09

8.  1,2,3-Triazole-heme interactions in cytochrome P450: functionally competent triazole-water-heme complexes.

Authors:  Kip P Conner; Preethi Vennam; Caleb M Woods; Matthew D Krzyaniak; Michael K Bowman; William M Atkins
Journal:  Biochemistry       Date:  2012-07-31       Impact factor: 3.162

Review 9.  Drug-Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV.

Authors:  Kimberly K Scarsi; Kristin M Darin; Catherine A Chappell; Stephanie M Nitz; Mohammed Lamorde
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

10.  Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone.

Authors:  Wen H Lin; Hwa-Ping Feng; Craig R Shadle; Terry O'Reilly; John A Wagner; Joan R Butterton
Journal:  Eur J Clin Pharmacol       Date:  2014-07-05       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.